Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine

The Pediatric Infectious Disease Journal
Ajoke Sobanjo-ter MeulenLuwy K Musey

Abstract

Widespread use of 7-valent pneumococcal conjugate vaccine (PCV7) in children has led to significant reduction in pneumococcal disease in children and adults. However, diseases caused by serotypes not included in PCV7 have increased. A 15-valent pneumococcal conjugate vaccine (PCV15) containing serotypes in PCV7 and 8 additional serotypes (1, 3, 5, 6A, 7F, 19A, 22F, 33F) was developed and evaluated in toddlers 12 to 15 months of age. Ninety toddlers who completed an infant series with PCV7 received a single dose of either aluminum-adjuvanted PCV15, nonadjuvanted PCV15, or PCV7. Injection-site and systemic adverse events (AEs) were collected for 14 days postvaccination and serious AEs (SAEs) were collected for 30 days postvaccination. Solicited AEs included local (pain/tenderness, swelling, nodule and redness) and systemic (fatigue, arthralgia and myalgia) AEs. Serotype-specific immunoglobulin G (IgG) and opsonophagocytic (OPA) responses were measured immediately prior and 30 days postvaccination. Incidences of local and systemic AEs were comparable across vaccine groups. The majority of reported events, regardless of vaccine received, were transient and of mild to moderate intensity. No clinically significant differences were ob...Continue Reading

References

Apr 1, 1985·Statistics in Medicine·O Miettinen, M Nurminen
Jun 28, 2003·Pediatrics International : Official Journal of the Japan Pediatric Society·Güler KanraAudino Podda
Sep 9, 2006·Clinical and Vaccine Immunology : CVI·Robert L Burton, Moon H Nahm
Oct 14, 2008·Expert Review of Anti-infective Therapy·Michael R Jacobs
Jan 1, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sandra S RichterGary V Doern
Sep 15, 2009·Lancet·Katherine L O'BrienUNKNOWN Hib and Pneumococcal Global Burden of Disease Study Team
Dec 2, 2009·The Journal of Infectious Diseases·Tamara PilishviliUNKNOWN Active Bacterial Core Surveillance/Emerging Infections Program Network
Jul 1, 2010·Pediatrics·Nicola P KleinUNKNOWN Vaccine Safety Datalink
Mar 15, 2011·Vaccine·Susan S HuangJonathan A Finkelstein
May 25, 2011·Expert Review of Vaccines·Geraldine Blanchard-Rohner, Andrew J Pollard
Aug 3, 2011·Expert Review of Vaccines·Marta C Nunes, Shabir A Madhi
Feb 15, 2012·Vaccine·Jae-Hoon SongBernard Fritzell

❮ Previous
Next ❯

Citations

Sep 1, 2015·British Journal of Haematology·Ernest KucharMonika Karlikowska
Mar 1, 2016·Expert Opinion on Drug Safety·Susanna Esposito, Nicola Principi
May 15, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Shamez N Ladhani, Mary E Ramsay
Jun 2, 2016·Hospital Pediatrics·Miya E Bernson-Leung, Laura L Lehman
Sep 17, 2016·Pneumonia·Anukul T Shenoy, Carlos J Orihuela
Sep 23, 2016·Expert Review of Vaccines·Susanna Esposito, Nicola Principi
Apr 15, 2017·Expert Review of Vaccines·Robert CohenCorinne Levy
Nov 14, 2017·Expert Review of Vaccines·Michael E Pichichero
Oct 13, 2017·Expert Opinion on Biological Therapy·Nicola Principi, Susanna Esposito
Jan 7, 2020·Expert Review of Vaccines·T R ConversoL C C Leite
Aug 14, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sana S AhmedTamara Pilishvili
Sep 15, 2019·Molecular and Cellular Probes·Hesam DorostiYounes Ghasemi
Nov 10, 2020·Vaccine·Maile T PhillipsDaniel M Weinberger
Dec 21, 2019·Microbiology Spectrum·D E BrilesM J Crain

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.